



## **OxySure Systems, Inc. (OXYS) Announces Progress on CE Marking**

FRISCO, TX -- (Marketwired – September 24, 2013) - OxySure Systems, Inc. (OTCQB: OXYS) (“OxySure” or the “Company”) a medical technology company that has pioneered an FDA-approved solution to produce medically pure oxygen from dry, inert powders for emergency/short duration use today announced progress with regard to the CE Marking of its flagship product, the OxySure Model 615.

The Company received notice on September 12, 2013 of an opinion rendered by the Medicines and Healthcare products Regulatory Authority (MHRA) in the United Kingdom related to the classification of the OxySure Model 615 as a medical device. An opinion of this nature by a competent authority is a key step in the CE Marking process.

“We are pleased with this opinion from MHRA,” stated Mark Gilmore, Managing Partner of Aero Healthcare, OxySure’s partner in the United Kingdom. Added Gilmore, who oversees the CE Marking process: “In addition, we have already substantially completed our technical file for the CE Marking process and we plan to move forward post haste with our notified body on the next steps of the CE Marking of OxySure.”

The CE marking indicates a product’s compliance with European Union legislation and enables the free movement and sale of products within the European market. CE Marking will allow OxySure’s approved products to be sold in approximately 31 countries in the European Economic Area (EEA), comprising the 28 Member States of the European Union and the European Free Trade Association (EFTA) countries of Iceland, Norway, and Liechtenstein. As of January 1, 2012, the population of the European Union was approximately 503.5 million people.

### **About OxySure Systems, Inc.**

OxySure is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. For more information please visit us at [www.OxySure.com](http://www.OxySure.com).

## **Contact Information**

DreamTeamGroup

Indianapolis, IN

[www.DTG.fm](http://www.DTG.fm)

317-623-3050

[Editor@DTG.fm](mailto:Editor@DTG.fm)

Barwicki Investor Relations

Andrew Barwicki

President

516-662-9461

[Andrew@Barwicki.com](mailto:Andrew@Barwicki.com)